Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + gemcitabine/cisplatin + SBRT versus gemcitabine/cisplatin for metastatic nasopharyngeal carcinoma
ChiCTR1900025341Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2019
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of camrelizumab, gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: 2-year progression-free survival. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
camrelizumabgemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1900025341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025341.